Global Blood Takes HOPE In Sickle Cell After Pulmonary Fibrosis Failure
GBT440 is not efficacious enough in studies of idiopathic pulmonary fibrosis, but the drug was well-tolerated at twice the exposure in the treatment of sickle cell disease, the drug's lead indication.
You may also be interested in...
Late-breaker presentations for Darzalex in multiple myeloma and Imbruvica in CLL will showcase "practice-changing" results in front-line settings. Other highlights include new treatments for beta-thalassemia, such as Acceleron's and Celgene's luspatercept.
Public Company Edition: Denali launched this year's largest biopharma IPO. Also, Valeant sold notes to retire older debt, while bluebird, Blueprint and others capitalized on data presented at ASH.
Once high-flying Novo Nordisk has been sending out M&A signals as it seeks a solution to weak growth, so analysts aren't surprised to see the Danish diabetes giant stalking US-based Global Blood Therapeutics.